PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

Phase 2 Completed 12 enrolled GPCR Therapeutics, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.

Timeline

Start: 2015-02
Primary completion: 2015-11
Completion: 2015-11

Outcome

Met primary endpoint

paper Eleven of 12 participants (92%) met the primary endpoint of collecting ≥ 5.0 × 106 CD34+ cells/kg within two leukapheresis sessions PMID 41636886 ↗

Publications

Sukhtankar DD, Cardarelli PM, Jalilizeinali B, Setia G, Kim G, Chang LW, Tsai CY, Caculitan NG, Schuster MW. Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplant. Ann Hematol. 2026 Feb 4;105(3):86. doi: 10.1007/s00277-026-06858-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TG-0054	Unknown	3.14 mg/kg	Intravenous
Background	G-CSF	Unknown	10 ug/kg	Subcutaneous